Vanguard Fiduciary Trust’s Prime Medicine PRME Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.82M Buy
764,633
+47,631
+7% +$158K ﹤0.01% 2489
2026
Q1
$2.5M Buy
+717,002
New +$2.73M ﹤0.01% 2453

Other funds holding PRME

Vanguard Fiduciary Trust's PRME Position: Q2 2026 in Review

Vanguard Fiduciary Trust increased its Prime Medicine (PRME) stake by 6.6% in Q2 2026, buying an estimated $158K and bringing the position to 764,633 shares worth $2.82M. The position accounts for ﹤0.01% of the portfolio, ranked #2489.

Vanguard Fiduciary Trust first reported a position in PRME in Q1 2026 and has held it in 2 quarters since. 186 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • Vanguard Fiduciary Trust held 764,633 shares of Prime Medicine worth $2.82M as of Q2 2026.
  • Vanguard Fiduciary Trust bought 47,631 Prime Medicine shares in Q2 2026, an estimated $158K.
  • Prime Medicine made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #2489 holding.
  • Vanguard Fiduciary Trust first reported a position in Prime Medicine in Q1 2026 and has held it in 2 quarters since.
  • 186 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.